LaNova Medicines Announces the IND Approval of LM-101 by NMPA
-
2022-11-15
-
Share:
Shanghai, November 15th, 2022 – LaNova Medicines Ltd. announced that the investigational new drug (IND) of LM-101, an anti-SIRPα monoclonal antibody, has been approved by China NMPA.